2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.
Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.
Unlike other chemotherapy-resistant cancers that have seen developments in treatments, pancreatic cancer is lacking beneficial improvements of other treatments, states Philip.
According to Philip, it is expected that pancreatic cancer will be the second leading cause of cancer mortalities by 2020. Most of the patients with pancreatic cancer have metastatic disease, making the only way to control the natural history of the disease is by getting better systemic treatments.
Related Content: